{"product_id":"covetrus-five-forces-analysis","title":"Covetrus Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCovetrus faces moderate supplier leverage, strong buyer bargaining from consolidated clinics, niche threats from specialized competitors, and regulatory plus technology-driven pressures shaping margins and growth.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Covetrus’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003cp\u003eGet the complete, consultant-grade report with force-by-force ratings, visuals, and actionable implications to inform investment or strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Pharmaceutical Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe veterinary supply chain is concentrated among large pharma firms—Zoetis, Boehringer Ingelheim, and Elanco—who together accounted for roughly 60–70% of global animal health sales in 2024, giving them strong supplier power. They sell essential, often patent-protected drugs, so veterinary practices depend on timely access, which boosts these manufacturers’ leverage over pricing and terms. Covetrus must maintain close partnerships and negotiate volume contracts to secure inventory and protect margins for its distribution business. In 2024 Covetrus reported 6.8% of net sales from product distribution, highlighting dependence on supplier stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTiered Pricing and Rebate Structures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers use tiered pricing and volume rebates that can shift 3–6 percentage points of gross margin for distributors like Covetrus, with manufacturers tying rebates to quarterly volume and SKU mix targets; missed targets in 2024 reportedly cost distributors up to $20–30M in lost rebates in peer channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Clinic Sales Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cplarge pharma now sells high-volume drugs direct to consolidated vet groups with recent deals showing channels capturing up of veterinary drug volumes in us corporate clinics cutting out distributors and trimming covetrus margin leverage. intermediary role weakens as manufacturers target higher gross margins show supplier bargaining power rose for top suppliers. respond must sell tech data services inventory automation ehr integrations vendors can easily replicate that recover operating through saas fees. if delays productizing these beyond months revenue at risk could exceed annually.\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of raw materials and specialized medical equipment strengthened bargaining power amid global logistics volatility through 2025, with container freight rates spiking 85% YoY in late 2021–2022 and remaining 20–30% above pre‑pandemic levels into 2024–25, letting suppliers prioritize buyers or lift wholesale prices.\u003c\/p\u003e\n\u003cp\u003eAny production or shipping disruption for critical animal‑health products lets suppliers reroute allocations to higher‑margin channels or impose 5–15% price increases; Covetrus must either absorb margins (hurting FY profit) or pass costs to vets and risk client churn.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLogistics volatility persisted into 2025: freight rates ~20–30% above 2019\u003c\/li\u003e\n\u003cli\u003eSupplier price shocks observed: typical increases 5–15%\u003c\/li\u003e\n\u003cli\u003eAllocation risk: suppliers can favor larger distributors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Proprietary Technology Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Covetrus expands hardware and diagnostics, reliance on specialized microchips and precision sensors gives those suppliers high bargaining power; shortages in 2024-25 saw semiconductor lead times hit 20+ weeks, raising component costs ~15% industry-wide.\u003c\/p\u003e\n\u003cp\u003eThis dependency risks delaying production timelines and widening gross margins for proprietary devices; a single-source sensor can force price concessions or inventory build-up that ties up working capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024-25 chip lead times ~20+ weeks\u003c\/li\u003e\n\u003cli\u003eComponent cost rise ~15% industry-wide\u003c\/li\u003e\n\u003cli\u003eSingle-source suppliers = higher price\/availability risk\u003c\/li\u003e\n\u003cli\u003eInventory or price pressure can widen device gross margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier consolidation boosts leverage, rebates hit margins, chip shortages spike price risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers (Zoetis, Elanco, Boehringer) held ~60–70% market share in 2024, raising bargaining power; tiered rebates shift 3–6 ppt gross margin and missed targets cost peers $20–30M. Direct sales to consolidated vet groups captured 15–20% of volumes, raising supplier leverage ~10% (2023–24). Chip lead times 20+ weeks and component costs +15% (2024–25) add 5–15% price shock risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop supplier share\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebate impact\u003c\/td\u003e\n\u003ctd\u003e3–6 ppt GM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect channel share\u003c\/td\u003e\n\u003ctd\u003e15–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChip lead times\u003c\/td\u003e\n\u003ctd\u003e20+ weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComponent cost rise\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Covetrus, this Porter's Five Forces overview uncovers competitive drivers, supplier and buyer power, substitute threats, and entry barriers to assess pricing influence, profitability risks, and strategic defensive opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, one-sheet Porter's Five Forces summary for Covetrus—instantly highlights competitive pressures and serves as a ready-to-use slide or decision aid.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Veterinary Practices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rise of corporate groups like Mars Veterinary Health (owner of VCA, ~1,200 clinics) and national chains has shifted bargaining power to buyers; these groups buy at scale and pushed Covetrus to accept double-digit contract discounts and tailored service-level agreements to keep share. In 2024, consolidated groups accounted for roughly 30–40% of US clinic revenue, so retaining a few high-volume accounts materially affects Covetrus’s top line and margin pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhile Covetrus’s software integration adds some stickiness, switching costs for basic medical supplies stay low for independent clinics; a 2024 AVMA survey found 62% of clinics compare three+ wholesalers for price, and 18% switched suppliers in the past year for savings under 5%. This ease of switching forces Covetrus to refresh loyalty programs and improve service—Covetrus reported 2024 distribution margin pressure and increased A\/R investments to retain customers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Transparency and Digital Comparison\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpby late digital procurement platforms made price transparency standard in animal health of us veterinary practices used comparison tools rising to per mckinsey vet channel data so managers can scan distributors for lowest meds or equipment real time. this customer empowerment cuts covetrus ability sustain premium pricing on non-exclusive skus pressuring gross margins reported margin vulnerable commoditized lines. automated repricing and supplier-switching reduce switching costs raise buyer leverage.\u003e\n\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Integrated Ecosystems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomers now demand that practice management software, pharmacy services, and supply tools interoperate; this trend boosts Covetrus’s retention potential but raises buyer expectations for uptime, integrations, and updates.\u003c\/p\u003e\n\u003cp\u003eBuyers can demand premium technical support and frequent releases; in 2024 surveys 62% of vet practices said integration quality influenced vendor loyalty, increasing switch risk if performance falters.\u003c\/p\u003e\n\u003cp\u003eIf integrations underperform, customers can threaten full-system replacement, giving them leverage over pricing, SLAs, and roadmap priorities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of practices cite integration as key (2024)\u003c\/li\u003e\n\u003cli\u003eHigh support\/SLA demands raise cost to serve\u003c\/li\u003e\n\u003cli\u003ePoor performance → elevated churn\/switch risk\u003c\/li\u003e\n\u003cli\u003eOpportunity to lock-in via ecosystem depth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative Prescription Fulfillment Options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePet owners increasingly demand prescriptions fillable at third-party pharmacies and online retailers like Chewy, cutting clinic pharmacy revenue—US online pet med sales reached about $2.4 billion in 2024, up 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThat revenue loss forces Covetrus to consider lowering fees for its prescription-management tools; Covetrus reported 2024 revenues of $2.2 billion, with services tied to pharmacy workflows under margin pressure.\u003c\/p\u003e\n\u003cp\u003eCovetrus must help vets quantify in-clinic value—faster turnaround, adherence counseling, and loyalty—so clinics can retain Rx volume and justify premiums to pet owners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThird-party online Rx sales: $2.4B (2024)\u003c\/li\u003e\n\u003cli\u003eCovetrus revenue: $2.2B (2024)\u003c\/li\u003e\n\u003cli\u003eClinic value props: speed, adherence, loyalty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ leverage crushes margins: Covetrus faces price pressure and high switch risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers hold strong leverage: consolidated groups (30–40% US clinic revenue in 2024) and price‑sensitive independents force double‑digit discounts and SLA tweaks, pressuring Covetrus’s 2024 gross margin of 24.1% and $2.2B revenue. Digital price tools (68% use in 2024, ~75% in 2025) and $2.4B online pet med sales raise switch risk despite software stickiness; integration quality (62% cite) now drives loyalty.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCovetrus revenue\u003c\/td\u003e\n\u003ctd\u003e$2.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e24.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated groups share\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline pet med sales\u003c\/td\u003e\n\u003ctd\u003e$2.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePractices using price tools\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration importance\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eCovetrus Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Covetrus Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders or mockups; it’s the full, professionally formatted document ready for download and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747056365945,"sku":"covetrus-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/covetrus-five-forces-analysis.png?v=1772194679","url":"https:\/\/matrixbcg.com\/products\/covetrus-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}